EYPT: DME Phase III results are the pivotal next catalyst after wet AMD trials missed their primary endpoint
EyePoint Inc. (EYPT) reported that its LUGANO and LUCIA trials for wet AMD did not meet the primary endpoint, but secondary results support continued development of DURAVYU. The company's fully enrolled DME Phase III trials, expected to report in early Q4 2027, are the next key catalyst, according to a UBS conference transcript.
How this was made

The 30-second read
Why it matters
Wet AMD primary endpoint miss increases clinical risk, but continued focus on DURAVYU and an upcoming DME Phase III readout window provide a forward-looking catalyst.
Market read
Traders may re-rank the company’s near-term catalyst from wet AMD to DME Phase III timing, while maintaining caution due to the primary endpoint miss.
What to watch
The piece provides no effect sizes, safety outcomes, or whether the DME trials are likely to confirm efficacy, so near-term trading may be driven more by broader biotech risk appetite than by this roadmap alone.
Background
The article summarizes EyePoint’s development status following wet AMD trial results and outlines the expected timing for fully enrolled DME Phase III readouts.
Ticker impact
EyePoint says wet AMD trials missed the primary endpoint, but secondary findings support continued focus on DURAVYU, with DME Phase III readout expected in early Q4 next year.
Likely mixed-to-negative sentiment as wet AMD primary endpoint miss offsets secondary support, while traders refocus on the next DME Phase III catalyst timeline.
The article is a conference transcript summary with no new numeric results, but it clearly reframes the development roadmap and the next expected readout window.
Market effects
Highlights how endpoint misses can redirect investor focus to alternative indications and later-stage readouts within ophthalmology.
No clear regional market linkage beyond US-listed biotech sentiment.
Limited, as the catalyst is company-specific clinical timing rather than a global macro or regulatory event.
Counterpoint
Secondary findings supporting DURAVYU could reduce downside versus a full failure narrative, making the wet AMD miss less damaging than feared.
Key entities
- companyEyePoint, Inc.
Subject of the article; wet AMD trials missed the primary endpoint, but secondary findings support continued focus on DURAVYU, with DME Phase III readouts expected in early Q4 next year.
- productDURAVYU
EyePoint’s therapy referenced as the continued focus after wet AMD trial results.
- clinical_programDME Phase III trials
Fully enrolled trials expected to read out together in early Q4 next year.
